Drug Profile
Flunarizine - Xenon Pharmaceuticals
Alternative Names: XEN 007Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Class Antiepileptic drugs; Antimigraines; Piperazines; Sedating antihistamines; Vascular disorder therapies
- Mechanism of Action Calcium channel antagonists; Dopamine receptor antagonists; Histamine H1 receptor antagonists; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Absence epilepsy
- No development reported Migraine
Most Recent Events
- 29 Nov 2023 University of British Columbia terminates phase II trial in Absence epilepsy (In children, Adjunctive treatment, Treatment-resistant, In adolscents) in Canada (PO) because the enrollment wasn't as predicted and there were not enough numbers to show statistical significance (NCT06153186)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Migraine in Canada
- 31 Dec 2020 Xenon Pharmaceuticals has patents pending for XEN 007 in the US